New York, NY – February 24, 2025

美国纽约州纽约市——2025年2月24日

- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, showcases an innovative strategy for T cell engineering that leverages the pro-inflammatory properties of interleukin 2 (IL-2) with the objective to enhance CAR T cell efficacy against solid tumors, at the American Association for Cancer Research – Immuno-oncology (AACR-IO), taking place on February 23-26, 2025 in Los Angeles, CA.

Cellectis（“公司”）（泛欧交易所成长板：ALCLS - 纳斯达克：CLLS），一家处于临床阶段的生物技术公司，利用其开创性的基因编辑平台开发挽救生命的细胞和基因疗法，展示了一种创新的T细胞工程策略，该策略利用白细胞介素2（IL-2）的促炎特性，旨在增强CAR-T细胞对实体瘤的疗效。这一展示将在2025年2月23日至26日于加利福尼亚州洛杉矶举行的美国癌症研究协会-免疫肿瘤学（AACR-IO）会议上进行。

.

。

The data are presented in a poster:

数据以海报形式呈现：

CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN-edited allogeneic CAR T-cells without associated IL-2 toxicity

CAR诱导合成工程FAP-IL2v免疫细胞因子的表达，增强TALEN编辑的同种异体CAR T细胞的持久抗肿瘤活性，且无相关IL-2毒性。

Presenter:

主持人：

Shipra Das, Ph.D., Associate Director Immuno-Oncology, at Cellectis.

Shipra Das，博士，Cellectis公司免疫肿瘤学副总监。

Date/Time:

日期/时间：

February 25,

2月25日，

2025,

2025，

1:45-4:45 p.m. PT

下午1:45-4:45（太平洋时间）

Session

会话

: Poster Session B

：海报会议 B

CAR T-cell therapies have transformed the treatment landscape for specific hematological malignancies and have shown promising preliminary efficacy in solid tumors.

CAR T细胞疗法已经改变了特定血液系统恶性肿瘤的治疗格局，并在实体瘤中显示出有希望的初步疗效。

Recent studies suggest a link between the

最近的研究表明两者之间存在联系

in vivo

体内

expansion and persistence of CAR-T cells and enhanced therapeutic outcomes in patients. The co-administration of interleukin-2 (IL-2) has been demonstrated to improve CAR T-cell engraftment, expansion, and functionality in preclinical models but poses toxicity risks at high doses.

CAR-T细胞的扩增和持久性以及患者治疗效果的增强。白细胞介素-2（IL-2）的共同给药已被证明在临床前模型中可以改善CAR-T细胞的植入、扩增和功能，但在高剂量下存在毒性风险。

Using Cellectis’ TALEN

使用Cellectis的TALEN技术

®

®

gene editing technology, we developed ‘Smart CAR T cells’ with the ability to express a CAR-inducible IL-2 variant (IL-2v) immunocytokine, potentiated by tumor-specific cues for localized activity within the solid tumor microenvironment (TME).

通过基因编辑技术，我们开发了“智能CAR-T细胞”，这种细胞能够在肿瘤特异性信号的刺激下表达一种CAR诱导的IL-2变体（IL-2v）免疫细胞因子，并在实体瘤微环境（TME）中发挥局部活性。

CAR-inducible expression of this recombinant FAP

CAR诱导的这种重组FAP的表达

scFv

单链抗体片段

-IL2v boosts anti-tumor activity of engineered CAR T-cells both

-IL2v 增强了工程化 CAR T 细胞的抗肿瘤活性

in vitro

体外

and

和

in vivo

体内

. Notably, the enhancement of CAR T-cell activity mediated by IL-2v relies on its anchoring to the FAP protein, which is uniquely present in the TME, thus minimizing the systemic toxicity typically associated with circulating free IL-2 cytokines.

特别是，IL-2v介导的CAR T细胞活性增强依赖于其锚定在TME中独特存在的FAP蛋白上，从而最大限度地减少了通常与循环游离IL-2细胞因子相关的全身毒性。

This proposed cellular engineering strategy would represent an effective and safe method to substantially improve CAR T cell expansion and anti-tumor activity, while confining IL-2 activity to the tumor microenvironment.

该拟议的细胞工程策略将代表一种有效且安全的方法，可在大幅改善CAR T细胞扩增和抗肿瘤活性的同时，将IL-2活性限制在肿瘤微环境中。

The poster is published on

海报发布于

Cellectis’ website

Cellectis的网站

.

。

Download the PDF file

下载PDF文件